UP!

NEO $15.39

NEO target price
15.39
0
0
NeoGenomics Laboratories, Inc.
Type
Public
Traded as NASDAQ: NEO
Industry Biotechnology, Health care
Founded 2002
Headquarters Fort Myers, Florida, United States
Area served
Worldwide
Key people
Douglas M. VanOort (Chairman and CEO)
Number of employees
1000 (2017)
Website neogenomics.com

NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is a high-complexity CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics.

Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US, with laboratories in Florida, California, Tennessee, and Texas.

NeoGenomics first received state and national-level laboratory certifications in 2002. 3 years later in 2005, the company developed a technical-only service model using FISH.

In 2013, the company launched its sequencing platform and was listed on the Nasdaq Stock Market as NEO. In 2014, NeoGenomics launched molecular tests including BTK and CALR mutation analysis.

In 2015, NeoGenomics acquired Clarient, Inc. and its subsidiary company, Clarient Diagnostic Services, Inc. , a national cancer diagnostics laboratory with capabilities in immunohistochemistry for solid tumor cancers from GE Healthcare. Clarient is headquartered in Aliso Viejo, California; with an ancillary laboratory in Houston, Texas.

In November 2017, NeoGenomics will establish their first headquarters outside the United States in Rolle, Switzerland.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q3 2022 2022-11-02 Future report Set alerts
Q2 2022 2022-08-09 -0.16 -0.16
Q1 2022 2022-04-27 -0.20 -0.20
Q4 2021 2022-02-23 -0.14 -0.14
Q3 2021 2021-11-04 -0.08 -0.08
Q2 2021 2021-08-06 -0.01 -0.01
Q1 2021 2021-05-05 -0.04 -0.04
Q4 2020 2021-02-24 0.14 0.14
Q3 2020 2020-10-27 0.00 0.00
Q2 2020 2020-07-28 -0.04 -0.06

Ratings

2016-07-09 Reiterated Rating Craig Hallum Buy
2016-07-08 Reiterated Rating BTIG Research Buy $10.00
2016-05-11 Initiated Coverage Roth Capital Buy $10.00
2016-04-28 Boost Price Target Benchmark Co. Buy $8.00 to $9.00
2016-03-11 Initiated Coverage Benchmark Co. Buy $8.00
2016-03-03 Reiterated Rating BTIG Research Buy $9.00
2016-01-07 Initiated Coverage Janney Montgomery Scott Buy $11.00
2015-11-02 Boost Price Target Craig Hallum Buy $8.00 to $10.00
2015-11-01 Reiterated Rating BTIG Research Buy $9.00
2015-10-26 Reiterated Rating William Blair Buy
2015-10-21 Reiterated Rating BTIG Research Buy $7.00
2015-09-28 Reiterated Rating BTIG Research Buy $8.00
2015-09-06 Reiterated Rating William Blair Outperform
2015-09-03 Reiterated Rating Roth Capital Buy
2015-07-24 Reiterated Rating BTIG Research Buy $8.00
2015-07-13 Boost Price Target Roth Capital $7.00 to $7.50
2015-07-12 Reiterated Rating Roth Capital Buy $7.00 to $7.50
2015-07-09 Reiterated Rating BTIG Research Buy $7.00
2015-07-06 Reiterated Rating Roth Capital Buy $7.00 to $7.00
2015-06-23 Initiated Coverage BTIG Research Buy $7.00
2015-06-22 Initiated Coverage BTIG Research Buy $7.00
2015-04-13 Set Price Target Roth Capital Buy $7.00
2014-05-14 Initiated Coverage Dawson James Buy $6.00
2014-05-12 Initiated Coverage Longbow Research Buy $6.00
2014-05-12 Initiated Coverage Roth Capital Buy $6.00
2014-02-14 Initiated Coverage Stephens Overweight $6.00
2014-01-08 Initiated Coverage William Blair Outperform
2013-10-02 Boost Price Target Societe Generale Hold €50.00 to €54.00
2013-04-25 Downgrade Ladenburg Thalmann Buy to Neutral
2013-02-14 Reiterated Ladenburg Thalmann Buy $3.50 to $3.75
2016-07-09 Reiterated Rating Craig Hallum Buy
2016-07-08 Reiterated Rating BTIG Research Buy $10.00
2016-05-11 Initiated Coverage Roth Capital Buy $10.00
2016-04-28 Boost Price Target Benchmark Co. Buy $8.00 to $9.00
2016-03-11 Initiated Coverage Benchmark Co. Buy $8.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
KINDERHOOK PARTNERS, LP 9.66%  (4848334) ACPW / NEO / PLPM /
VAN OORT DOUGLAS M Chairman and CEO 3.74%  (1875000) NEO /
DENT MICHAEL T 2.76%  (1384150) NEO /
HIPP RAYMOND R 0.54%  (272016) NEO /
JONES STEVEN C Executive VP of Finance 0.45%  (226251) NEO /
CARDOZA GEORGE CFO 0.44%  (221089) NEO /
Robison William J 0.37%  (183348) MWIV / NEO /
Johnson Kevin C 0.26%  (128309) NEO /
HOREL ROBERT H. Vice President andGM PathLogic 0.10%  (51218) NEO /
ALBITAR MAHER Chief Medical Officer 0.10%  (48492) NEO /
HANNAH ALISON L. 0.09%  (45449) NEO /
BRODIE STEVEN G. Chief Scientific Officer 0.07%  (32619) NEO /
TETRAULT LYNN A. 0.04%  (21782) NEO /
CROWTHER BRUCE K 0.03%  (17202) NEO / WTFC /
GASPARINI ROBERT P Chief Science Officer 0.02%  (8439) NEO /
SHOVLIN ROBERT J. Chief Operating Officer 0.01%  (6550) NEO /
ROSS STEVEN A CIO 0.01%  (4500) NEO /